Clinical trials: Carcinoma, Hepatocellular
Hepatocellular Carcinoma
Efficacy of Sequential TACE and PVE on the Resectability of Hepatitis B Related HCC
A primary hepatocellular carcinoma (HCC) is generally regarded as unresectable if the future liver remnant (FLR)≤40％ of total liver volume in patient with underlying liver disease, such as hepatitis B.
- Trial name
- TACEPVE (NCT00834158)
- Testing
- TACE, PVE
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Eastern Hepatobiliary Surgery Hospital
Hepatocellular Carcinoma
Ablation Combined With PD-1 in HCC: Phase II Study
This is a Phase 2, single arm, single center study designed to evaluate the safety and tolerability of radiofrequency or microwave ablation combined with PD-1 monoclonal antibody in patients with hepatocellular carcinoma(HCC)…
- Trial name
- NCT04652440
- Testing
- PD-1 monoclonal antibody, Radiofequencey or microwave ablation
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Sun Yat-sen University
Advanced Adult Hepatocellular Carcinoma
An Individualized Anti-Cancer Vaccine in Advanced Hepatocellular Carcinoma Subjects
This is an open-label, single site, Phase IIA clinical trial to investigate the safety and efficacy of an individualized anti-cancer vaccine (CRCL-AlloVax) in advanced HCC patients.
- Trial name
- NCT02409524
- Testing
- AlloVax, AlloStim, CRCL
- Where
- Thailand
- Volunteers
- 15 people
- Sponsor
- Mirror Biologics, Inc.
Patients With Resectable Hepatocellular Carcinoma Who Are at High Risk of Recurrence or Metastasi
TQB2450 Combined With Anlotinib Hydrochloride in the Perioperative Treatment of Hepatocellular Carcinoma Hydrochloride Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma With a High Risk of Recurrence or Metastasis
In this study, single cell transcriptome sequencing will be performed on the tissue samples punctured and the surgically resected specimens to explore the gene mutation sites related to efficacy
- Trial name
- NCT04888546
- Testing
- Anlotinib hydrochloride capsules＋ TQB2450 injection
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Chinese Academy of Medical Sciences
Infection
Telaprevir Plus Standard of Care (SOC) in HCV Associated Hepatocellular Carcinoma (HCC)
The goal of this clinical research study is to learn if the antiviral combination of telaprevir, pegylated Interferon Alfa 2a (PegIFN alfa-2a) and ribavirin (RBV) can prevent the virus from coming back after the liver transplant.
- Trial name
- NCT01821963
- Testing
- Pegylated Interferon Alfa 2a, Ribavirin, Telaprevir
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- M.D. Anderson Cancer Center
Hepatocellular Carcinoma, Microwave Ablation
Donafenib as Adjuvant Therapy Following Ablation for Recurrent HCC
This study intends to evaluate the efficacy and safety of low-dose adjuvant donafenib after thermal ablation for early recurrent HCC within Milan criteria.
- Conditions
- Hepatocellular Carcinoma, Microwave Ablation, Donafenib, Recurrent Tumor
- Trial name
- NCT06609876
- Testing
- Thermal ablation, Donafenib
- Where
- China
- Volunteers
- 108 people
- Sponsor
- Sun Yat-sen University
Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer
3-Tesla MRI Response to TACE in HCC (Liver Cancer)
This pilot clinical trial examines how well different imaging biomarkers acquired using 3-Telsa magnetic resonance imaging (MRI) methods perform in determining treatment response to transarterial chemoembolization (TACE) in…
- Conditions
- Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Localized Resectable Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer
- Trial name
- NCT02057874
- Testing
- 3 Tesla Magnetic Resonance Imaging, Magnevist® (Intravenous (IV) administration of MRI contrast agent)
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Advanced Hepatocellular Carcinoma (HCC), Metastatic Liver Cancer
Dual-Target GPC3/B7-H3 CAR-NK Cells for Advanced HCC
open-label trial of an allogeneic dual-target CAR-NK product directed against GPC3 and B7-H3 for adults with advanced hepatocellular carcinoma.
- Trial name
- DUET-HCC (NCT07500220)
- Testing
- EB-G3B7-NK dual-target CAR-NK cells, Fludarabine, Cyclophosphamide
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Beijing Biotech
Hepatocellular Carcinoma (HCC)
Artificially Intelligent Model for Accurate Detection of HCC
Purpose: Integrating comprehensive information on hepatocellular carcinoma (HCC) is essential to improve its early detection. The investigators aimed to develop a model with multi-modal features (MMF) using artificial…
- Trial name
- NCT06637059
- Testing
- observational study
- Where
- China
- Volunteers
- 1,092 people
- Sponsor
- Zhejiang University
Liver Diseases, Hepatocellular Carcinoma
bTAE-HAIC Combined With System Therapy for Intermediate-advanced Huge HCC
This study intends to evaluate the efficacy and safety of blank- microsphere transcatheter arterial embolization-hepatic arterial infusion chemotherapy of oxaliplatin, 5-fluorouracil and leucovorin (bTAE-HAIC) plus Lenvatinib and…
- Conditions
- Liver Diseases, Hepatocellular Carcinoma, Immunotherapy, Camrelizumab
- Trial name
- NCT06061276
- Testing
- bTAE-HAIC, Lenvatinib, Camrelizumab
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Sun Yat-sen University
Hepatocellular Carcinoma
GPC3 Targeted Fluorescence Image Guided Surgery of Hepatocellular Carcinoma
This study is to evaluate whether intraoperative fluorescence imaging targeting GPC3 can aid improve the surgical accuracy of hepatocellular carcinoma.
- Trial name
- NCT05047510
- Testing
- Anti-GPC3-IRDye800CW
- Where
- 2 sites in China
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Chinese Academy of Sciences
Hepatocellular Carcinoma
A Study of LY2157299 in Participants With Unresectable Hepatocellular Cancer (HCC)
The main purpose of this study is to evaluate safety and tolerability of LY2157299 when combined with sorafenib in Japanese hepatocellular carcinoma (HCC) participants.
- Trial name
- NCT02240433
- Testing
- LY2157299, Sorafenib
- Where
- 3 sites in Japan
- Volunteers
- 9 people
- Sponsor
- Eli Lilly and Company
HCC, Adjuvant Therapy
Adjuvant Anti-PD-1 Therapy in Resected Hepatocellular Carcinoma
Early hepatocellular carcinoma (HCC) recurrence (driven by residual tumors) and late recurrence (driven by de novo tumors) exhibit distinct biological behaviors, suggesting differential therapeutic vulnerabilities.
- Conditions
- HCC, Adjuvant Therapy, Recurrence, Immune Checkpoint Inhibitor
- Trial name
- NCT07379489
- Testing
- PD-1 Inhibitors
- Volunteers
- 300 people
- Sponsor
- Tongji Hospital
Hepatocellular Carcinoma
MicroRNAs as Diagnostic Biomarkers in Hepatocellular Carcinoma Among Somali Patients
Hepatocellular carcinoma (HCC) is the most common primary liver cancer and is the third leading cause of cancer that related death in the worldwide.
- Trial name
- NCT03227510
- Volunteers
- 126 people, healthy volunteers welcome
- Sponsor
- People's Friendship University of Russia
Hepatocellular Carcinoma
Radiofrequency Ablation Combined With Recombinant Human Adenovirus Type 5 in the Treatment of Hepatocellular Carcinoma.
The primary reason for recurrence of hepatocellular carcinoma after radiofrequency ablation (RFA) is the micro-metastatic lesion that has not been ablated and inactivated in the transitional area.Some clinical trials have…
- Trial name
- NCT03790059
- Testing
- H101, RFA
- Where
- 2 sites in China
- Volunteers
- 160 people
- Sponsor
- Southwest Hospital, China
Carcinoma, Hepatocellular
Dose Escalation Study Using Proton Beam Radiotherapy for Hepatocellular Carcinoma
The radical treatment for Hepatocellular carcinoma (HCC) is surgery. However, it is only for 10 to 20% of all patients and 10 to 30% of them have relapsed every year after surgery.
- Trial name
- NCT00662246
- Testing
- respiratory gated proton beam radiotherapy
- Where
- South Korea
- Volunteers
- 24 people
- Sponsor
- National Cancer Center, Korea
Hepatocellular Carcinoma
Efficacy and Safety of TACE in Combination With ICIs for HCC: a Real-world Study
The purpose of this study is to evaluate the safety and efficacy of transarterial chemoembolization (TACE) in combination with immune checkpoint inhibitors (ICIs) in patients with hepatocellular carcinoma (HCC) .
- Trial name
- CHANCE001 (NCT04975932)
- Testing
- TACE+ICIs, TACE
- Where
- China
- Volunteers
- 826 people
- Sponsor
- Zhongda Hospital
Advanced Hepatocellular Carcinoma
Phase I/II Study of Amplitude-Modulated Electromagnetic Fields in the Treatment of Advanced Hepatocellular Carcinoma
The goal of this study is to investigate the safety and feasibility of treating patients with advanced hepatocellular carcinoma with a noninvasive device administering low level of amplitude-modulated electromagnetic fields.
- Trial name
- TheraBionic (NCT00534664)
- Testing
- TheraBionic device
- Where
- Brazil
- Volunteers
- 40 people
- Sponsor
- University of Sao Paulo
Hepatitis B, Hepatocellular Carcinoma (HCC)
TAF Monotherapy Versus ETV Combined With TAF on the Efficacy and Prognosis of Immunotherapy for Hepatitis B-Related Hepatocellular Carcinoma
Study Objective: To compare the efficacy and prognosis of systemic cancer therapy between TAF monotherapy and ETV plus TAF combination therapy in patients with unresectable, advanced hepatitis-B-related hepatocellular carcinoma…
- Trial name
- NCT07253220
- Testing
- The arm will receive combination therapy (entecavir 0.5 mg once daily plus TAF 25 mg once daily); after HBV DNA becomes undetectable, the combination group will switch to TAF monotherapy., TAF monotherapy
- Volunteers
- 120 people
- Sponsor
- Sun Yat-sen University
Carcinoma, Hepatocellular, Metastatic Colorectal Cancer
Vandetanib-eluting Radiopaque Embolic Beads in Patients With Resectable Liver Malignancies
This is a pilot, open label single arm phase 0 window of opportunity study of vandetanib-eluting radiopaque beads in patients with resectable liver malignancies.
- Trial name
- VEROnA (NCT03291379)
- Testing
- BTG-002814
- Where
- United Kingdom
- Volunteers
- 8 people
- Sponsor
- Boston Scientific Corporation